Jeff Ryckman: How many patients make it to CAR-T without ever seeing radiotherapy?

Jeff Ryckman, Radiation Oncologist and Assistant Professor at West Virginia University shared a post by David Russler-Germain on X/Twitter, adding:

”How many patients make it to CAR-T without ever seeing radiotherapy? Bet it’s the majority. Why aren’t we making noise about the 5-10% PFS benefits with appropriate use of cost effective RT? Is avoidance of toxic salvage therapy not a priority?”

Quoting the mentioned post by David Russler-Germain, Oncology Instructor at Siteman Cancer Center.

”CART cells are revolutionizing B-NHL treatment. But… Let’s not sweep under the rug:

(1) ~$400k product, ~$1M “total package”
(2) ~1/4 patients required ICU care
(3) Non-relapse mortality ~10%.

We need to acknowledge the downsides to make CART cells cheaper, faster, and safer.”

For the article click here.
Source: Jeff Ryckman/Twitter